Overall, by enhancing the sensitivity of NSCLC cells to cisplatin through a mechanism involving KiSS-1, epigenetic drugs appear to be promising for the treatment of NSCLC patients, including those bearing cisplatin-resistant tumors. Here, KISS1 is linked to non-small cell lung carcinoma.